Avoidance and epinephrine are essential. Families also deserve access to treatment aimed at protecting their children from a life-threatening reaction to an accidental bite.
Share your experiencePrivate submissions. No public stories without separate permission.
Estimated Kaiser members living with food allergies.
The need for clear treatment pathways extends far beyond one family’s experience.
Kaiser reports 12.9 million members as of June 30, 2026, excluding Risant Health affiliates.[19] CDC’s 2024 national estimates of diagnosed food allergy are 5.3% among children and 6.7% among adults.[17][20] Applying those rates to total membership gives approximately 684,000–864,000 people, rounded here to 700,000–900,000.
This is a rough prevalence-based scenario range, not a measured Kaiser count or statistical confidence interval. Kaiser’s population may differ from the national population. It estimates affected members, not distinct households, treatment denials, or people eligible for OIT or SLIT.
Make food-allergy treatment access clear, individualized, and accountable.
After our daughter’s reaction, knowing how to respond to the next emergency was only part of what we needed.
We administered epinephrine and took her to the emergency department, where she needed further treatment.
Kaiser diagnosed her food allergies and prescribed emergency medication. In our discussions with Kaiser, we were actively counseled against pursuing food-allergy immunotherapy. We were not offered a pathway to active treatment. We sought specialist care outside Kaiser and began navigating private treatment and its costs ourselves.
Our concern is that families are left to discover, evaluate, and finance additional treatment options on their own.
We want to know how many other Kaiser families have faced the same gap.
Food allergies can cause anaphylaxis, a potentially life-threatening reaction. Managing that risk reaches into ordinary life: every meal, every caregiver, and every decision about whom to trust with a child’s safety.[1]
An emergency plan answers what to do when something goes wrong. It does not answer whether treatment could make a future exposure less dangerous.
Oral immunotherapy (OIT) uses measured doses of an allergen that are swallowed. Sublingual immunotherapy (SLIT) uses small doses held under the tongue. Both aim to make accidental exposure less dangerous by helping a person tolerate food that previously triggered an allergic reaction.[2][3]
Published studies show meaningful benefits. The results below are a reason for an informed treatment discussion and an individualized assessment.
Another option is omalizumab (Xolair), approved for food allergy from age one to reduce reactions from accidental exposure while avoidance continues.[4]
Food allergies affect families across the country. National surveys document a substantial historical rise—and a large burden today.
CDC’s national survey found an increase from 4.0% in 2007 to 6.5% in 2018 among children ages 0–17: a 2.5-percentage-point rise, or 62.5% relative growth over 11 years.[16]
Parents or guardians reported whether their child had a food or digestive allergy in the previous 12 months. These were not all confirmed by clinical testing.
CDC’s report published in January 2026 puts the figure at 5.3% of children ages 0–17 in 2024. Behind that percentage are families managing food choices, childcare, and the possibility of a serious reaction every day.[17]
This is a household survey estimate of diagnosed food allergy, not the same measure used in the earlier trend.
The dates matter. The 62.5% rise describes 2007–2018, not the current annual growth rate. CDC changed its survey in 2019, so the older and newer figures cannot be joined into one trend. The newer estimate was 5.8% in 2021 and 5.3% in 2024; those figures do not establish continued rapid growth.[18][17]
A problem this widespread deserves an organized treatment pathway. Kaiser should plan for it as a population-health responsibility, with clear access to specialist assessment and appropriate treatment.
An accidental bite can send a child to the emergency department. OIT and SLIT aim to build protection against that danger, including anaphylaxis. In these studies, many treated children could eat amounts of their allergen that they previously could not tolerate. The results below show what they could safely consume during supervised testing.
IMPACT · Ages 1–3 · 146 children
Tolerated a 5 g peanut-protein challenge after 134 weeks of treatment: 68 of 96 children receiving OIT, versus 1 of 50 receiving placebo.
21% of the OIT group still passed the 5 g peanut-protein challenge after 26 weeks of avoidance, versus 2% with placebo.
Treatment burden: Dosing reactions were common. Twenty-one of 96 OIT participants received epinephrine for dosing reactions.
Read the IMPACT trial · 2022 ↗Two-center trial · Ages 1–4 · 50 children
Tolerated a 4.443 g peanut-protein challenge after 36 months of treatment: 15 of 25 children receiving SLIT, versus 0 of 25 receiving placebo.
48% of the SLIT group passed the challenge after three months off treatment, versus 0% with placebo.
Treatment burden: Mouth and throat itching was more common with SLIT. This was a small trial; it does not establish zero risk.
Read the peanut SLIT trial · 2024 ↗NUT CRACKER · Ages 4+ · 65 participants
Tolerated a 4 g cashew-protein dose at the study endpoint: 44 of 50 treated participants, versus 0 of 15 untreated controls.
All 44 could still tolerate the 4 g cashew-protein dose after at least six months of continued daily maintenance dosing. This was not a test of remission off treatment.
Treatment burden: Three of 50 treated participants (6%) received epinephrine for reactions at home. This study was not randomized.
Read the NUT CRACKER study · 2022 ↗Desensitization means being able to consume more of the allergy-triggering food without a reaction while continuing treatment. Remission here means passing a challenge after a specified period off treatment; it does not establish a permanent cure.
These studies measured how much food participants could tolerate under supervision; they did not measure a reduction in deaths. Treatment can itself cause allergic reactions, including anaphylaxis, so its benefits and risks require individual assessment. The studies used different treatment plans, food amounts, and follow-up periods and do not directly compare OIT with SLIT. They do not establish the same outcomes for infants under one or for cashew SLIT. All food quantities above are protein amounts, not home-dosing instructions.
Families deserve access to a serious discussion of these benefits, risks, and uncertainties—and a clear explanation when treatment is discouraged.
Kaiser’s public food-allergy guidance emphasizes avoiding allergens, recognizing reactions, and using emergency medication. That guidance matters. It does not, by itself, explain how a member can access active treatment.[5]
Our experience does not establish what happens in every Kaiser clinic. That is why we are asking other members to contribute theirs.
A family’s access can depend on three separate decisions: whether it can see an experienced specialist, whether clinical visits are covered, and whether the treatment preparation or program fee is covered.
Public-source review · September 26, 2026 · Northern California access where specified
| Payer | OIT policy and access | Food SLIT |
|---|---|---|
 Kaiser PermanenteNorthern California HMO | Our experience: counseled against immunotherapy; no active-treatment pathway offered. Published rule: outside specialist referrals require prior authorization. We did not locate a public NorCal food-OIT eligibility policy in this review.[7] | We did not verify a general NorCal food-SLIT coverage policy. Our family’s experience is not proof of a systemwide exclusion. |
 Aetna | Restrictive policy: CPB 0038 classifies food OIT other than FDA-approved peanut OIT as experimental, investigational, or unproven. Its separate Palforzia policy is product-specific.[8][9] Latitude nevertheless reports participation in select NorCal Aetna networks.[10] | CPB 0038 restricts SLIT drops. Its named tablet exceptions treat environmental allergies, not food allergy.[8] |
 Cigna | Some local network access: Latitude reports participating NorCal EPO/PPO plans.[10] Policy 0070 does not establish blanket coverage for food-based OIT; benefits and individual service decisions still matter.[11] | Policy 0070, effective April 15, 2026, explicitly excludes sublingual antigen-extract drop preparations from coverage or reimbursement.[11] |
 Anthem Blue Cross | Provider-reported access: Latitude lists participating NorCal EPO/PPO plans. This establishes a potential specialist route, not universal OIT coverage.[10] | Food-SLIT coverage not established by the sources reviewed. |
 Blue Shield of California | Provider-reported access: Latitude lists participating NorCal plans, including Covered California. Exact network and service benefits require verification.[10] | Food-SLIT coverage not established by the sources reviewed. |
 UnitedHealthcare | Provider-reported access: Latitude lists participating NorCal EPO/PPO plans. We did not verify blanket coverage for noncommercial food OIT.[10] | Food-SLIT coverage not established by the sources reviewed. |
What the local access evidence actually shows. Latitude Food Allergy Care reports insurance coverage for OIT office visits, while charging a separate program fee that insurance does not cover. Its network list and billing description are provider statements, not payer guarantees. A covered consultation does not override a treatment exclusion.[10]
Do not mistake an old product policy for current access. Palforzia’s official REMS site now states that it has been withdrawn from the U.S. market and new patients cannot start it. A payer’s remaining Palforzia policy does not establish access to food-based OIT.[12]
The evidence does not support saying every competitor covers OIT or SLIT. It does show that some competing plans give members routes to specialist OIT care with insurance contributing to clinical visits. Kaiser members deserve an equally concrete account of what is available inside the system and when outside care will be authorized.
A recommendation against treatment should identify the reason: the child’s clinical circumstances, the evidence, unavailable expertise, or a coverage exclusion. Families should not have to guess which one is deciding their care.
A healthcare system should measure its success in the harm it helps people avoid. For a family facing food allergy, that means taking the possibility of preventing a future life-threatening reaction seriously—before the next accidental bite.
This connects to a broader problem in U.S. healthcare: fragmented care and payment for individual services can weaken accountability for a person’s long-term health. CMS has described how that fragmentation leaves patients navigating incomplete information and conflicting advice.[21] Families should not have to become their own care coordinators to find out whether preventive treatment is available.
For someone who already has a food allergy, prevention means reducing the danger of future reactions. OIT and SLIT deserve an individualized assessment of their potential benefits, treatment risks, and the evidence for that patient. An emergency plan should sit alongside that assessment.
Kaiser’s integrated model should make prevention easier to organize. It brings coverage and care delivery together. Our expectation is simple: use that structure to offer a clear path to assessment, appropriate treatment, and sustained follow-up. The ambition should be fewer crises and safer everyday lives.
An integrated payer and care-delivery system has the tools to make skilled, repeatable treatment more accessible.
Kaiser’s model can be highly efficient: prepaid coverage, coordinated specialists, shared records, and follow-up within one system. Kaiser itself describes these features as ways to align incentives, reduce duplication, and improve outcomes.[13]
Food-based OIT can use ordinary food products rather than a proprietary pharmaceutical. Canadian allergy guidelines explain that, in this model, costs arise primarily from clinicians’ services.[14] Published work also describes SLIT preparations made from inexpensive real foods, although other SLIT protocols use commercial extracts and have different costs.[15]
The complete treatment still requires expertise, preparation, supervised escalation, monitoring, and ongoing support. Low ingredient cost does not establish low total cost or guaranteed savings. But a costly proprietary drug is not an inherent requirement of these food-based approaches.
That makes this an opportunity to organize care. In our view, Kaiser is particularly well placed to standardize appropriate protocols, train teams, provide regional specialist access, and measure both outcomes and costs. Those are precisely the advantages an integrated system is meant to deliver.
For our family, that promise did not translate into a treatment pathway. We were counseled against pursuing immunotherapy and looked outside the system. We see that as a wasted opportunity.
Show members what the model delivers. Publish treatment criteria, participating clinics, assessment wait times, outside-referral decisions, and program outcomes. Where evidence is still developing, explain the route to expert review or a monitored program.
Four concrete changes we are asking Kaiser Northern California to make.
Make treatment availability, eligibility, referral steps, and coverage criteria understandable and accessible.
Explain which options may be appropriate, which are not, and why—including whether and when to revisit the decision.
Provide a clear process for outside referrals when appropriate care is not available within Kaiser.
Give families written explanations and understandable options for reviewing treatment and coverage decisions.
Research and public guidance behind this page.
Evidence differs by treatment, age, and allergen.
Who we are. Kaiser Allergy Watch is run by a volunteer group of parents. We are not affiliated with Kaiser Permanente. Questions and requests: privacy@kaiserallergywatch.org.
What we collect. Only what you enter in the form. Your email address makes your submission identifiable to us, so it is not anonymous. Please leave out member IDs, children's full names, birth dates, and medical records.
How we use it. The organizers read submissions privately to understand how members access food-allergy care. Nothing is published automatically, and we will ask you first before sharing any identifiable story or quotation. We will contact you only if you checked the follow-up box. We never sell your information.
How long we keep it. Until the campaign ends. We delete everything within 90 days after that.
Your choices. Email privacy@kaiserallergywatch.org to see, correct, or delete your submission.